EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 25th, 2021 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations • Washington
This Executive Employment Agreement (the “Agreement”), made between Neoleukin Therapeutics, Inc., a Delaware corporation (the “Company”), and Holly Vance (the “Executive” and, collectively with the Company, the “Parties”), is entered into as of September 29, 2020, to be effective as of the Effective Date (as defined below).
FIRST AMENDMENT TO LEASELease • March 25th, 2021 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is made as of November 5th, 2020, by and between ARE-SEATTLE NO. 28, LLC, a Delaware limited liability company (“Landlord”), and NEOLEUKIN THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
AMENDMENT NO. 1License Agreement • March 25th, 2021 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 to the Exclusive Start-Up License Agreement (this “Amendment No. 1”) effective as of July 24, 2020 (the “Amendment No. 1 Effective Date”), is entered into between the University of Washington (“University”), and Neoleukin Corporation, formerly known as Neoleukin Therapeutics, Inc. (“Company”).
